A drug that has been associated with increased suicide risk in children may pose the same danger to adults.
A study in the journal BMC Medicine has analysed unpublished data on paroxetine, a drug that is used to treat millions of depressed people in Britain every year. Patients taking paroxetine are more likely to attempt suicide than those taking a placebo, according to researchers based at the University of Oslo in Norway.
Paroxetine, which is sold as Seroxat and Paxil, belongs to a class of drugs called selective serotonin re-uptake inhibitors (SSRIs). These drugs increase the availability in the brain of serotonin, a chemical linked to mood and emotions.
In October 2004, the US Food and Drug Administration insisted that labels carry warnings about the use of paroxetine in children. This followed analysis of clinical trials that showed an increase in suicidal thoughts and behaviours in children taking the drug.
Britain's Committee on Safety of Medicines had issued warnings much earlier, in June and September 2003. They advised practitioners that paroxetine should not be used to treat depressive illness in children and adolescents under the age of 18 years. A few months later, in December 2003, the committee extended this warning to cover all SSRIs except fluoxetine (Prozac) for the treatment of depression in children.
But both the UK and US agencies concluded that the data did not confirm an increased risk in adults. They said that the benefits of taking these drugs outweighed the risks for depressed people.
In February 2005, researchers published studies on drug-company data that were submitted for safety review to the London-based Medicines and Healthcare products Regulatory Agency. They found no evidence that SSRIs increase the risk of suicide in adults, but warned doctors that such dangers could not be ruled out (D. Gunnell, J Saperia and D. Ashby Br. Med. J. 330, (385) (386) (387) (388) .
Their analysis of paroxetine was incomplete because the data supplied by the manufacturer, GlaxoSmithKline, did not allow researchers to distinguish between suicidal thoughts and suicide attempts.
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